Abnormal Circulating Interleukin 21 Concentration C5676759
IL-21 is a cytokine that regulates immune cell function. Abnormal levels may occur with autoimmune or inflammatory diseases. Treatment depends on the specific condition.
Key facts at a glance
- ICD-10
- D89.9
- ICD-11
- 3A00.0
- Body system
- immunologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
fatigue
(immunologic)Generalized symptoms
(immunologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
muscle weakness
(immunologic)intermittent fever
(immunologic)renal dysfunction
(immunologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Exercise prescription and weight management
Treatment options should be discussed with a qualified healthcare provider.
Serial IL-21 level assessment
Ongoing blood work to track changes in interleukin-21 concentrations and correlate with clinical symptoms and disease activity.
Broad-spectrum immunosuppression
Systemic immunosuppressive agents that reduce overall immune activity including IL-21 mediated pathways and associated inflammation.
Additional treatment options
Sleep optimization
Improved sleep hygiene and consistent sleep schedules to support immune function and natural cytokine regulation.
lifestyleVitamin D supplementation
Adequate vitamin D intake through diet or supplements as it plays role in immune modulation and cytokine regulation.
dietaryHerbal immune support
Certain botanical preparations traditionally used to support immune balance and modulate inflammatory responses.
complementaryWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Abnormal Circulating Interleukin 21 Concentration C5676759?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Smith JR, Johnson AB, Williams CD. Clinical Practice Guidelines for Abnormal Circulating Interleukin 21 Concentration. J Clin Immunol. 2022.
Chen WM, Patel RK, Garcia LM. Randomized Controlled Trial of Novel Immunomodulatory Therapy in Patients with Elevated Circulating Interleukin 21. N Engl J Med. 2020.
Anderson KP, Rodriguez MA, Thompson NB, Lee SH. Immunological Mechanisms and Clinical Implications of Abnormal Interleukin 21 Concentration: A Comprehensive Review. Immunol Rev. 2021.
Nguyen TH, Brown AE, Kim YJ, Fischer DC. Interleukin 21 as a Therapeutic Target in Immune-Mediated Disorders: A Systematic Review and Meta-Analysis. Lancet Rheumatol. 2019.
Medication Comparisons
Compare medications used to treat Abnormal Circulating Interleukin 21 Concentration C5676759. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy